Preferred place of death (PPOD) in PD, PSP and MSA
Objective: To ascertain whether people with PD, PSP and MSA have a PPOD Background: Achieving a PPOD is felt to be an important factor in…High repressive activity of olive extracts on the cell line model of Parkinson disease against ROS induction
Objective: Neurodegenerative diseases including Parkinson’s disease (PD) mostly accompany with induction of high ROS in neuronal cells. It is believed that unusual level of ROS…Exploratory Analysis of Electrocortical Signal Complexity in Patients with Progressive Supranuclear Palsy and Corticobasal Degeneration
Objective: We evaluated self-similarity of electrocortical activity as expression of brain signal complexity in patients clinically affected by Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration…Clinical Response to 72-h Lumbar CSF Drainage in Idiopathic Normal Pressure Hydrocephalus associated with Parkinsonism: Timing and Correlates
Objective: To evaluate timing and clinical correlates of motor response after 72-h lumbar CSF drainage in patients with Normal Pressure Hydrocephalus (iNPH) associated with parkinsonism.…Parkinson Disease Clinical Subtypes Predict Dementia and Mortality Risk
Objective: To identify PD clinical subtypes based on patterns of motor, cognitive, and psychiatric symptoms; to assess the clinical utility of each subtype in predicting…Predictors of Retention for Carbidopa/Levodopa Intestinal Gel in Parkinson Disease
Objective: To identify predictors of discontinuation of levodopa/carbidopa intestinal gel therapy. Background: Although levodopa/carbidopa intestinal gel (LCIG) is an established treatment for Parkinson's disease complicated…Healthcare disparities in patients with Parkinson’s disease: A comprehensive literature review and call to action
Objective: To review the literature on healthcare disparities in Parkinson’s care in the United States and to initiate a community education program targeted at an…Identification of protein biomarker/s in CSF of Parkinson’s disease (PD) with cognitive impairment
Objective: i. To identify CSF protein biomarker/s in Parkinson's disease (PD) with cognitive impairment using LC-MS/MS proteomics. ii. To estimate the level of known AD…Phenotypic spectrum of Progressive Supranuclear Palsy in a Tunisian cohort
Objective: To describe the clinical and imaging features of the different phenotypes of progressive supranuclear palsy (PSP). Background: PSP is a neuropathologically defined disease entity…Differentiation of Progressive Supranuclear Paralysis from Multisystem Atrophy and Parkinson’s Disease by Cranial MRI
Objective: To assess differences in cranial MRI between progressive supranuclear palsy (PSP), multisystem atrophy (MSA) and Parkinson's disease (PD) that support the clinical diagnosis. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.